J. Deal

发表

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos

Wei Liu, Huichun Zhu, Dac Dinh, 2014, Journal of medicinal chemistry.

Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction.

D. Bouzida, M. Pairish, S. Yamazaki, 2012, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological activity of novel polycyclic aza-amide FKBP12 ligands.

E. Lunney, S. Bender, R. Showalter, 2006, Journal of medicinal chemistry.

Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant

Huichun Zhu, Benjamin J. Burke, John Charles Kath, 2014 .

Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.

D. Matthews, C. Janson, S. Webber, 1993, Journal of medicinal chemistry.

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

Paolo Vicini, Deepak Dalvie, Chengyi Zhang, 2017, Journal of medicinal chemistry.

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).

Ping Chen, Hong Shen, M. Pairish, 2020, Journal of medicinal chemistry.

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.

N. Sach, Hong Shen, M. McTigue, 2014, Journal of medicinal chemistry.

Synthesis and biological evaluation of novel 2,6-diaminobenz[cd]indole inhibitors of thymidylate synthase using the protein structure as a guide.

C. Janson, C. Bartlett, M. Varney, 1995, Journal of medicinal chemistry.

Crystal-structure-based design and synthesis of benz[cd]indole-containing inhibitors of thymidylate synthase.

C A Morse, R. Bacquet, C. Bartlett, 1992, Journal of medicinal chemistry.

Structure-based design of substituted diphenyl sulfones and sulfoxides as lipophilic inhibitors of thymidylate synthase.

D. Matthews, C. Janson, R. Bacquet, 1997, Journal of medicinal chemistry.

Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.

N. Sach, M. McTigue, H. Zou, 2013 .

Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant

N. Sach, H. Zou, R. Kania, 2014 .